Pulmonary Disease Management in Cystic Fibrosis pulmonary disease

Pulmonary Disease Management in Cystic Fibrosis Pulmonary complications remain the leading cause of morbidity and mortality in patients with cystic fibrosis (CF). The underlying defect in the CFTR protein results in dehydrated airway secretions, impaired mucociliary clearance, and persistent bacterial colonization, ultimately leading to chronic inflammation, bronchiectasis, and progressive respiratory decline. Airway clearance is the cornerstone of management. Chest physiotherapy, oscillatory devices, and positive expiratory pressure techniques are routinely applied. Inhaled therapies such as hypertonic saline and recombinant human DNase reduce mucus viscosity and enhance clearance. Antimicrobial therapy is essential to control airway infections. While early colonization often involves Staphylococcus aureus and Haemophilus influenzae, chronic infection with Pseudomonas aeruginosa dominates in older patients. Inhaled antibiotics (tobramycin, aztreonam, colistin) are used for long-term suppression, while intravenous regimens are reserved for acute exacerbations. Treatment is tailored according to regular sputum cultures to optimize pathogen-specific coverage. Anti-inflammatory strategies aim to mitigate airway damage. Long-term azithromycin has both anti-inflammatory and anti-biofilm effects. High-dose ibuprofen in selected adolescents may slow lung function decline. Systemic corticosteroids are generally reserved for complications such as allergic bronchopulmonary aspergillosis (ABPA). A major advance in CF care has been the development of CFTR modulators, which target the basic molecular defect. Ivacaftor has shown dramatic benefits in gating mutations, while combination therapies such as lumacaftor/ivacaftor and tezacaftor/ivacaftor extend treatment to patients with F۵۰۸del mutations. The triple therapy elexacaftor/tezacaftor/ivacaftor (Trikafta®) has transformed outcomes, significantly improving lung function, reducing pulmonary exacerbations, and enhancing quality of life in the majority of patients. For patients with advanced disease, supportive respiratory care includes long-term oxygen therapy and non-invasive ventilation in chronic respiratory failure. Lung transplantation remains the final option for those with severe, refractory decline despite maximal therapy. Adjunctive measures such as pulmonary rehabilitation, optimized nutrition, and vaccination (influenza, pneumococcal) play a crucial role in maintaining overall health. Conclusion: Modern management of CF lung disease combines established therapies for airway clearance and infection control with novel CFTR modulators that address the root defect. This integrated approach has markedly improved survival and quality of life, shifting the paradigm of CF care from supportive to disease-modifying therapy.